Roche (RHHBY) announced that it had received European approval for MabThera to treat patients with pemphigus vulgaris ((PV)). This approval is a good one, because it will help expand the market opportunity for MabThera. Especially, since the company had already received approval for the drug in the United States back in June of 2018. Roche needs as many approvals as it can get for this drug, because its mainstay drug Herceptin is facing and will face competition in terms of biosimilars.
European Approval For Rare Disease
The European approval for MabThera was for